ArticleEuropean heart journal. Case reports2026
Genetic cardiomyopathy unmasked by pregnancy: X-linked dystrophinopathy presenting as peripartum cardiomyopathy-a case report.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peripartum cardiomyopathy (PPCM) is an uncommon cause of heart failure occurring towards the end of pregnancy or in the months following delivery. Although often considered idiopathic, emerging evidence suggests a significant genetic contribution in some patients. Case summary: We report a 31-year-old woman who presented 10 weeks postpartum with symptoms of advanced heart failure. Transthoracic echocardiography revealed a severely reduced left ventricular ejection fraction (18%). Cardiac magnetic resonance imaging confirmed severe systolic dysfunction with non-ischaemic late gadolinium enhancement. After exclusion of other causes, PPCM was diagnosed. She was initiated on guideline-directed heart failure therapy and bromocriptine for lactation suppression. As part of the ongoing evaluation, endomyocardial biopsy revealed persistence of parvovirus B19 without histological evidence of active myocarditis. Genetic testing was initiated, and results later identified a pathogenic X-linked deletion of exons 44-50 in the dystrophin (DMD) gene, consistent with cardiac-restricted dystrophinopathy. The patient has remained clinically stable under ongoing therapy. Discussion: This case underscores the importance of considering genetic testing in PPCM. The identification of an X-linked dystrophin gene deletion was unexpected, as the patient had no neuromuscular symptoms. Such mutations may manifest as isolated cardiomyopathy in female carriers, with pregnancy serving as a precipitating physiological stressor. Identifying a genetic cause enables optimized management and facilitates targeted family screening.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.